New LDL-cholesterol lowering therapies: Pharmacology, clinical trials, and relevance to acute coronary syndromes

A.H. Sahebkar; Gerald Watts

doi:10.1016/j.clinthera.2013.06.019

New LDL-cholesterol lowering therapies: Pharmacology, clinical trials, and relevance to acute coronary syndromes

A.H. Sahebkar
, Gerald Watts

Research output: Contribution to journal › Review article

175 Citations (Scopus)

Abstract

Background: Reduction in plasma low-density lipoprotein cholesterol (LDL-C) is a fundamental treatment for the prevention of acute coronary syndromes (ACS). Although statin therapy confers significant protection against ACS in both primary and secondary prevention, a considerable residual risk remains after intensive therapy. In addition, a significant proportion of high-risk patients do not achieve the optimal LDL-C goal recommended in the current guidelines (

Original language	English
Pages (from-to)	1082-1098
Journal	Clinical Therapeutics
Volume	35
Issue number	8
DOIs	https://doi.org/10.1016/j.clinthera.2013.06.019
Publication status	Published - 2013

Access to Document

10.1016/j.clinthera.2013.06.019

Cite this

@article{da2fde77897944e8a5b230dcc9e6374b,

title = "New LDL-cholesterol lowering therapies: Pharmacology, clinical trials, and relevance to acute coronary syndromes",

abstract = "Background: Reduction in plasma low-density lipoprotein cholesterol (LDL-C) is a fundamental treatment for the prevention of acute coronary syndromes (ACS). Although statin therapy confers significant protection against ACS in both primary and secondary prevention, a considerable residual risk remains after intensive therapy. In addition, a significant proportion of high-risk patients do not achieve the optimal LDL-C goal recommended in the current guidelines (",

author = "A.H. Sahebkar and Gerald Watts",

year = "2013",

doi = "10.1016/j.clinthera.2013.06.019",

language = "English",

volume = "35",

pages = "1082--1098",

journal = "Clinical Therapeutics",

issn = "0149-2918",

publisher = "Elsevier",

number = "8",

}

TY - JOUR

T1 - New LDL-cholesterol lowering therapies: Pharmacology, clinical trials, and relevance to acute coronary syndromes

AU - Sahebkar, A.H.

AU - Watts, Gerald

PY - 2013

Y1 - 2013

N2 - Background: Reduction in plasma low-density lipoprotein cholesterol (LDL-C) is a fundamental treatment for the prevention of acute coronary syndromes (ACS). Although statin therapy confers significant protection against ACS in both primary and secondary prevention, a considerable residual risk remains after intensive therapy. In addition, a significant proportion of high-risk patients do not achieve the optimal LDL-C goal recommended in the current guidelines (

AB - Background: Reduction in plasma low-density lipoprotein cholesterol (LDL-C) is a fundamental treatment for the prevention of acute coronary syndromes (ACS). Although statin therapy confers significant protection against ACS in both primary and secondary prevention, a considerable residual risk remains after intensive therapy. In addition, a significant proportion of high-risk patients do not achieve the optimal LDL-C goal recommended in the current guidelines (

U2 - 10.1016/j.clinthera.2013.06.019

DO - 10.1016/j.clinthera.2013.06.019

M3 - Review article

C2 - 23932550

SN - 0149-2918

VL - 35

SP - 1082

EP - 1098

JO - Clinical Therapeutics

JF - Clinical Therapeutics

IS - 8

ER -

New LDL-cholesterol lowering therapies: Pharmacology, clinical trials, and relevance to acute coronary syndromes

Abstract

Access to Document

Fingerprint

Cite this